Download PDF
Thromb Haemost 2011; 106(02): 383-385
DOI: 10.1160/TH11-03-0165
Letters to the editor
Schattauer GmbH

A cascade of thromboembolic processes in a patient with paroxysmal nocturnal haemoglobinuria terminated by treatment with eculizumab

Roger E. G. Schutgens
1   Department of Hematology/Van Creveldkliniek, University Medical Center Utrecht, The Netherlands
,
Kim A. B. M. Pruissen-Peeters
2   Department of Dermatology/Allergology, University Medical Center Utrecht, The Netherlands
,
Petra Muus
3   Department of Hematology, University Hospital Nijmegen, The Netherlands
› Author Affiliations
Further Information

Publication History

Received: 11 March 2011

Accepted after major revision: 21 April 2011

Publication Date:
25 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Miyata T, Yamada N, Iida Y. et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 1994; 330: 249-255.
    CrossrefPubMedGoogle Scholar
  • 2 Sugimori C, Chuhjo T, Feng X. et al. Minor population of CD55-. Blood 2006; 107: 1308-1314.
    CrossrefPubMedGoogle Scholar
  • 3 de Latour RP, Mary JY, Salanoubat C. et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 2008; 112: 3099-3106.
    CrossrefPubMedGoogle Scholar
  • 4 Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003; 102: 3587-3591.
    CrossrefPubMedGoogle Scholar
  • 5 Socie G, Mary JY, de Gramont A. et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996; 348: 573-577.
    CrossrefPubMedGoogle Scholar
  • 6 Hillmen P, Young NS, Schubert J. et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-1243.
    CrossrefPubMedGoogle Scholar
  • 7 Brodsky RA, Young NS, Antonioli E. et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111: 1840-1847.
    CrossrefPubMedGoogle Scholar
  • 8 Hillmen P, Muus P, Duhrsen U. et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110: 4123-4128.
    CrossrefPubMedGoogle Scholar
  • 9 Abe R, Shichishima T, Ogawa K. et al. Neutropenia due to parvovirus B19 infections in patients with paroxysmal nocturnal hemoglobinuria. Blood transfusion and natural infection cases. Acta Haematol 2006; 116: 245-248.
    CrossrefPubMedGoogle Scholar
  • 10 Kok RH, Wolfhagen MJ, Klosters G. A syndrome resembling thrombotic thrombocytopenic purpura associated with human parvovirus B19 infection. Clin Infect Dis 2001; 32: 311-312.
    CrossrefPubMedGoogle Scholar
  • 11 Young NS, Abkowitz JL, Luzzatto L. New Insights into the Pathophysiology of Acquired Cytopenias. Hematology Am Soc Hematol Educ Program. 2000: 18-38.
    PubMedGoogle Scholar
  • 12 Grunewald M, Siegemund A, Grunewald A. et al. Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size. Blood Coagul Fibrinolysis 2003; 14: 685-695.
    CrossrefPubMedGoogle Scholar
  • 13 Ninomiya H, Hasegawa Y, Nagasawa T. et al. Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity. Int J Hematol 1997; 65: 285-291.
    CrossrefPubMedGoogle Scholar
  • 14 Sloand EM, Pfannes L, Scheinberg P. et al. Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. Exp Hematol 2008; 36: 1616-1624.
    CrossrefPubMedGoogle Scholar
  • 15 Gralnick HR, Vail M, McKeown LP. et al. Activated platelets in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995; 91: 697-702.
    CrossrefPubMedGoogle Scholar
  • 16 Wiedmer T, Hall SE, Ortel TL. et al. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 1993; 82: 1192-1196.
    PubMedGoogle Scholar
  • 17 Qin X, Hu W, Song W. et al. Balancing role of nitric oxide in complement-mediated activation of platelets from mCd59a and mCd59b double-knockout mice. Am J Hematol 2009; 84: 221-227.
    CrossrefPubMedGoogle Scholar
  • 18 Kato GJ, Taylor JG. Pleiotropic effects of intravascular haemolysis on vascular homeostasis. Br J Haematol 2010; 148: 690-701.
    CrossrefPubMedGoogle Scholar
  • 19 Helley D, de Latour RP, Porcher R. et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica 2010; 95: 574-581.
    CrossrefPubMedGoogle Scholar
  • 20 Ziakas PD, Poulou LS, Pomoni A. Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review. Curr Vasc Pharmacol 2008; 6: 347-353.
    CrossrefPubMedGoogle Scholar
  • 21 Hillmen P, Lewis SM, Bessler M. et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253-1258.
    CrossrefPubMedGoogle Scholar
  • 22 Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2009; 113: 6522-6527.
    CrossrefPubMedGoogle Scholar